Medical Oncology
In 2002, colorectal cancer was the third most commonly diagnosed cancer in both men and women. Slightly more than 100,000 new cases of colorectal cancer are diagnosed per year and about 48,000 people die of the disease per year. During the past 3 decades, mortality from the disease has decreased as a testament to early diagnosis and better treatment modalities. This case highlights many aspects in the care and management of patients with colorectal cancer. The case deals with the management of nonmetastatic rectal cancer, follow-up recommendations for patients previously diagnosed and treated, and management of stage IV colorectal cancer.
At initial presentation in 1997, the patient noted hematochezia and underwent a complete staging workup that included a total colonoscopy with pathological tissue review, blood work, and imaging studies. The patient underwent a low anterior resection and was diagnosed as having a stage III, T1N1M0 rectal cancer. Such patients are at risk for both distant recurrences, typically in the liver, and local pelvic recurrence, which carries significant morbidity. For stage III disease with no postoperative or adjuvant therapy, both the distant and local failure rates are in the range of 50%. In 1990, a Consensus Development Conference sponsored by the National Institute of Health concluded that adjuvant therapy consisting of the combination of chemotherapy and radiation should become the standard in both stage II and stage III rectal cancers. 1 In cases such as this, where cancers are located very low near the sphincter, maintenance of continence is a common difficulty encountered and is most certainly aggravated by irradiation. However, using external beam therapy with 5000 to 5400 cGy, the local failure rate is halved. Of late there has been some debate that better surgical techniques using a total mesorectal excision, where there is sharp dissection around the integral mesentery of the hindgut, will decrease local failure rates and avoid the need for adjuvant radiation. This technique has not withstood the rigors of a prospective randomized multi-institutional trial.
Three clinical trials conducted in the 1980s showed a survival advantage for stages II and III rectal cancers where 5-fluorouracil (5-FU) was given concomitantly with the radiation. These trials conducted by the National Surgical and Adjuvant Breast Project, 2 the North Central Cancer Tumor Group, 3 and the GI Tumor Study Group 4 showed 5-FU-based chemotherapy with pelvic irradiation improved 5-year survival on average from 45% to 60%. The best method of delivery of the 5-FU is debated, but in general it is either given as a low-dose continuous infusion (200-250 mg/ m2/day) during the irradiation or as quicker infusions during the first and fifth weeks of irradiation. Additionally, 4 more months of 5-FU-based therapy are given to reach a total of 6 treatments. Again, how best to deliver the 5-FU is not clear, but as Moore and Haller 5 reviewed in their data, the standard has become the use of 5-FU and leucovorin for 6 months for patients with stage III colorectal cancer. The uses of levamisole or prolonged treatment regimens were not as efficient or efficacious as the combination of the 2-drug regimen for the 6-month period. This patient should have received combined modality adjuvant therapy.
Following diagnosis and treatment of colon cancer, careful and appropriate surveillance is necessary. This would entail a history and physical exam every 3 months for a 2-year duration and then twice a year for a total of 5 years. Given the size of the patient's lesion and the negative carcinoembryonic antigen (CEA) at diagnosis, following routine CEA levels would not be considered standard of care. Had the size of the patient's lesion invaded into or beyond the muscularis propria or had his initial CEA been elevated, then CEA values should be checked at each visit for the duration of the 5 years. As well, a colonoscopy should be done 1 year following the time of surgery and then repeated in 1 year if there is a finding of polyps or 3 years if there is no evidence of polyps.
After being followed for a year and a half, the patient's disease progressed and he was found to have metastatic spread of the cancer. At that time, the liver metastases were resectable and the patient underwent a wedge resection and complete proctectomy to remove the disease at the anastomosis site. Given the liver disease, the patient has now been upstaged to stage IV colon cancer and should have received appropriate chemotherapy for his advanced disease. At that time, the patient received 6 months of 5-FU and leucovorin. The best therapy of hepatic relapse such as occurred in this case is unclear. Resection of the metastatic lesions, although done commonly, really has only anecdotal evidence for justification. In the late 1990s, evidence was emerging that 2 new drugs given concomitantly with 5-FU were showing a higher progression free and overall survival in stage IV colorectal cancer. The use of irinotecan, 5-FU, and leucovorin emerged as the standard therapy in the United States and Canada. 6 However, regimens such as that used by DeGramont 7 in Europe containing oxaliplatin, 5-FU, and leucovorin were also showing similar advantages over the 5-FU/leucovorin therapy alone. A recently concluded intergroup trial comparing the 2 appears to be favoring the oxaliplatin-based therapy at least in terms of toxicity profile. In this case, where all recurrent disease has been resected, the use of the stage IV treatment data is an extrapolation, but the chance of micrometastatic disease is certainly above 90%. It is in this setting, where hepatic metastases were completely resected, that Kemeny 8 was able to show a survival advantage for patients treated with both systemic 5-FU/leucovorin and a hepatic artery infusion pump that delivers FUDR (an analog of 5-FU) directly into the liver. The control arm in this trial received hepatic resection and systemic 5-FU/leucovorin. Given these data, most oncologists would have treated the patient more aggressively following the liver resection.
After completing a 6-month treatment, the patient was then found to have a rising CEA. In this setting, the patient would merit a repeat colonoscopy; chest, abdominal, and pelvis CT scans; and a complete physical exam. Given the negative findings on the above procedures, a repeat CT scan every 3 months is in order until a source of the rising CEA is found. After 1 year of being followed, once again the patient was noted to have liver metastasis but, in contrast to the previous presentation, this time the disease was not resectable. In this scenario, the patient then becomes a candidate for salvage therapy.
When dealing with the issue of salvage chemotherapy, the number 1 issue is to consider the goal of treatment. In all scenarios, the goal is to achieve an improved quality of life, and potentially to prolong life without incurring too many deleterious side effects. Taking into account the patient's performance status and personal wishes are of utmost importance. As well, the results of complete blood counts, renal function, and liver enzymes often dictate which therapies can be offered. When addressing salvage therapies, the uses of 5-FU, leucovorin, irinotecan, oxaliplatin, capecitabine, and hepatic arterial chemotherapy with FUDR are all utilized alone or in combination. The rationale for the use of irinotecan or oxaliplatin has already been addressed previously and, in a patient who has not previously been treated with these agents, both would be of merit. VanCutsem 9 compared oral capecitabine with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer and found oral capecitabine achieved an at least equivalent efficacy compared with IV 5-FU/LV. Capecitabine demonstrated clinically meaningful safety advantages and the convenience of an oral agent. This drug has been studied in combination with irinotecan in early phase I and II trials and has shown antitumor effect in patients with colorectal cancer. Phase III data comparing this regimen to other regimens has not yet been presented.
At the time of presentation to Block Medical Center, the patient has clearly responded to the combination of irinotecan and capecitabine, but he is not tolerating the capacitabine. Given one goal of therapy is to provide an improved quality of life, it might be worth either continuing with the current regimen and altering the antiemetic therapy or switching the patient from capecitabine to fluorouracil and leucovorin along with the irinotecan. In either scenario, as long as the patient is responding to therapy, continuing with this modality would be within his best interest.
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Chronomodulated Chemotherapy
Today's cytotoxic agents have been through rigorous clinical trials to prove their safety and efficacy before they are released for use by community oncologists. There is now increasing evidence to suggest that the administration of these agents at the appropriate circadian phase can significantly increase the therapeutic index of certain chemotherapy drugs.
There is accumulating evidence that defects in the daily circadian rhythms enhance cancer risk. Wellcontrolled animal experiments show that environments that eliminate circadian integration of organ function accelerate the development of tumors in rodents. 1 In human studies, epidemiologists have found that shift work leading to sleep deprivation may increase cancer risk. It has already been observed that the circadian clock controls downstream cellular events by governing the expression of clockcontrolled genes that function in the rate-limiting steps of various biological pathways. 2 There is also accumulating evidence that clock genes regulate cellular proliferation and apoptosis in rapidly renewing tissues. 3 In cancer, the equilibrium between cell proliferation and cell death has shifted to excessive proliferation. Rhythmic changes in tissue function partially explain the circadian variation in sensitivity of rapidly proliferating tissues to the cytotoxic effects of chemotherapy. Studies with animal models have found that toxicities of many chemotherapeutic agents vary with the phase of the circadian cycle.
Since it is understood that normal physiologic ranges for every biological function are variable, circadian rhythms are natural cycles that evolved to take advantage of variations in light and temperature, thus enhancing survival. Biological economy demands that organismic tasks be initiated and completed at specific optimal times within important time-keeping cycles and in a certain order relative to one another. Lightdark cycle changes can lead and shift endogenous circadian cycles, and circadian cycle shifts can impact hormonal and other physiologic cycle regularity.
Because circadian physiologic processes alter drug absorption, distribution, metabolism, and excretion, dosages must be adjusted to meet the differing needs of target organs or tissues at varying times of the day. Studies so far suggest that there are different chronobiological cycles for normal cells and tumor cells. It appears that the goal is to time the administration of cancer drugs to the chronobiological cycles of tumor cells, making them more effective against the cancer and less toxic to normal tissues.
The biological rationale for applying circadian rules to the clinical treatment of cancer is compelling. Recent clinical data have confirmed the potential prognostic impact of circadian function in patients with advanced cancer. Colorectal cancer patients with distorted circadian function usually have a larger tumor burden, liver metastasis, and poorer performance status. On the other hand, patients with colorectal cancer who have normal rest-activity circadian rhythms had a 5-fold higher 2-year survival than patients with diminished rhythms. A recent phase 3 randomized clinical trial of untreated colorectal metastatic disease compared the administration of oxaliplatin, fluorouracil, and folinic acid at the optimum circadian phase to the conventional constant rate infusion. Ninety-three patients were assigned to chronotherapy, and another 93 were assigned to constant rate infusion. An objective tumor response was obtained in 47 (51%) of the chronotherapy group compared with an objective response rate in 27 (29%) of the continuous infusion rate group (difference of 21.5%; 95% CI, P = .003). Furthermore, chronotherapy was associated with a 5fold reduction in the rate of severe mucosal toxicity and the rate of peripheral neuropathy. 4 A case report of dramatic tumor response of bulky liver metastasis
